Treatment of diffuse subretinal fibrosis uveitis with rituximab

Kurt Spiteri Cornish, Lucia Kuffova, John Forrester

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.

Original languageEnglish
Pages (from-to)153-154
Number of pages2
JournalBritish Journal of Ophthalmology
Volume99
Issue number2
Early online date30 May 2014
DOIs
Publication statusPublished - Feb 2015

Fingerprint

Uveitis
Fibrosis
Immunosuppression
Adrenal Cortex Hormones
B-Lymphocytes
Therapeutics
Rituximab
Multifocal choroiditis

Keywords

  • Diffuse subretinal fibrosis uvetis (DUS)
  • rituximab
  • treatment

Cite this

Treatment of diffuse subretinal fibrosis uveitis with rituximab. / Spiteri Cornish, Kurt; Kuffova, Lucia; Forrester, John.

In: British Journal of Ophthalmology, Vol. 99, No. 2, 02.2015, p. 153-154.

Research output: Contribution to journalArticle

Spiteri Cornish, Kurt ; Kuffova, Lucia ; Forrester, John. / Treatment of diffuse subretinal fibrosis uveitis with rituximab. In: British Journal of Ophthalmology. 2015 ; Vol. 99, No. 2. pp. 153-154.
@article{326a57a772d24ab1baaa7d6cb5df80f5,
title = "Treatment of diffuse subretinal fibrosis uveitis with rituximab",
abstract = "Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.",
keywords = "Diffuse subretinal fibrosis uvetis (DUS), rituximab, treatment",
author = "{Spiteri Cornish}, Kurt and Lucia Kuffova and John Forrester",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",
year = "2015",
month = "2",
doi = "10.1136/bjophthalmol-2013-304686",
language = "English",
volume = "99",
pages = "153--154",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Treatment of diffuse subretinal fibrosis uveitis with rituximab

AU - Spiteri Cornish, Kurt

AU - Kuffova, Lucia

AU - Forrester, John

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2015/2

Y1 - 2015/2

N2 - Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.

AB - Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.

KW - Diffuse subretinal fibrosis uvetis (DUS)

KW - rituximab

KW - treatment

U2 - 10.1136/bjophthalmol-2013-304686

DO - 10.1136/bjophthalmol-2013-304686

M3 - Article

C2 - 24879811

VL - 99

SP - 153

EP - 154

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 2

ER -